June 19, 2013 /PRNewswire/ -- Below are experts from the
ProfNet network that are available to discuss timely issues in your coverage area. If you are interested in interviewing any of the experts, please contact them via the contact information at the end of the listing. To receive these updates by email, send a note to
firstname.lastname@example.org with the industries you cover, and we'll add you to the appropriate edition.
If you are in need of additional experts, you can also
submit a query to the hundreds of thousands of experts in our network. You can filter your request by institution type and geographic location to get the most targeted responses. The best part? It's free! Just fill out the
query form to get started.
If you have any questions or need assistance with any aspect of ProfNet, please drop us a note at
- Placing Mom on Medicaid
- Supreme Court Decision on Human Gene Patent
- SCOTUS Gene Patent Case
- Unanimous Supreme Court Decision on Patent Case
- Editorial Assistant – Mobile Marketer (NY)
- Reporter – The NewsTribune (IL)
- Online Copy Editor – Demand Media Studios (Anywhere)
OTHER NEWS & RESOURCES
- Media 411: Conference Season
- Freelancing With a Full-Time Job: What You Need to Know
- Networking Secrets of Freelancers
Placing Mom on Medicaid
Ronald Fatoullah, Esq.
Elder Law & Estate Planning Attorney
Mom has just been diagnosed with Alzheimer's disease and will need long-term care. Health care costs are skyrocketing. What do families need to know about planning when a medical emergency or a catastrophic illness strikes? Regarding Medicaid eligibility and benefits -- who should apply and when?"Fatoullah is available to discuss the topics that arise when caring for a parent. He is the founder and managing attorney of
& Associates, a
law firm that exclusively focuses on the legal and financial challenges of aging: elder law, estate planning, Medicaid eligibility, asset preservation, probate, wills, trusts, guardianships, veteran planning, and planning for same-sex couples.Website:
Supreme Court Decision on Human Gene Patents
ProfessorIIT Chicago-Kent College of Law "The Supreme Court has liberated human genes. This decision is great news for patients, doctors, and scientific researchers. Half of geneticists were impeded in their research by gene patents. Now they can begin the search for cures."In Association for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that human genes were not patentable since they are products of nature and not inventions. Andrews filed amicus
briefs in the trial court, appellate court and the U.S. Supreme Court representing medical organizations including the American Medical Association, the American Society of Human Genetics and the American College of Obstetricians and Gynecologists. She argued that a patent on genes was not only legally inappropriate, but also a threat to public health. For the past 10 years, Andrews has studied the impact of gene patents on health care and scientific research, receiving grants from the federal Department of Energy Human Genome Project and from the Robert Wood Johnson Foundation. Expert Contact:
SCOTUS Gene Patent Case
Co-director, Health Law & Policy Institute
University of Houston
Law Center"The decision makes sense, but it is a major change that has the potential to upset business expectations of biotech firms that have structured their businesses on the assumption that genes are patentable. One hears dire forecasts that invalidating gene patents will put a halt to biotechnology investment and innovation. Frankly, those fears seem overblown."Evans is available to explain the issues involved in the case, as well as what it means for research companies and the average citizen after the U.S. Supreme ruled that companies cannot patent human genes.Media Contact:
Unanimous Supreme Court Decision on Patent Case
Assistant Professor of Law
University of Houston
Law Center"We expected there to be a divided opinion from the Supreme Court on this issue. At oral argument, there wasn't a consensus regarding how to promote innovation while prohibiting something from nature to be patented. Instead, the Supreme Court issued a decisive opinion, where it unanimously held that isolated DNA is not to be patentable under the Patent Act. I think that several of us were expecting the court to use a fuzzy balancing test instead."Kumar is available to speak about the Supreme Court's decision in the gene patent case. Media Contact:
John T. Kling
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts